Table 4 Sensitivity analyse

Soo Kun Lim 2023 [17]

OWSA and PSA

N

the cost-effectiveness probability of dapagliflozin was 99.9%

the results were robust

Bao-Ngoc Nguyen 2023 [18]

scenario analyses and OWSA

If the efficacy of dapagliflozin in lowering MI, stroke, HFH, ACD, dialysis, eGFR and UACR declines was reduced by 3.5% per year after the first 2.5 years, the results remained similar in the

base case.

NA

the results were robust

Phil McEwan 2022 [20]

scenario analyses, OWSA, and PSA

1 For analyses that ran over a period of 10 years or fewer, dapagliflozin was generally expected to be dominant versus placebo

2 When patients were assumed to discontinue dapagliflozin treatment after 3 years, dapagliflozin remains highly

cost effective.

99.8% of simulations were cost effective in the UK, with 99% and 100% being cost effective in Germany and Spain, respectively.

the results

were robust

Satoshi Kodera 2022 [21]

scenario analyses, OWSA, and PSA

1 the scenario analysis based on the meta-analysis results: dapagliflozin remains cost- effectiveness in CKD 3a and CKD 3b

2 DAPA-CKD population: dapagliflozin remains cost- effectiveness in CKD 3a and CKD 3b

3 CKD with diabetes mellitus: dapagliflozin remains cost- effectiveness in CKD 3a and CKD 3b

4 Mortality reduction to 0%: dapagliflozin remains cost- effectiveness in CKD 3b but not in CKD 3a.

5 Mortality reduction to 15%: dapagliflozin remains cost- effectiveness in CKD 3b but not in CKD 3a.

6 hemodialysis reduction to 0%: dapagliflozin does not remain cost- effectiveness in CKD 3a and 3b.

7 Time horizon to 10 years: dapagliflozin remains cost-effectiveness in CKD 3b but not in CKD 3a.

8 Time horizon to 30 years: dapagliflozin remains cost- effectiveness in CKD 3a and CKD 3b

9 Renal function deterioration model: dapagliflozin remains cost-effectiveness in CKD 3a and CKD 3b

the cost-effectiveness probability of dapagliflozin was 52.6% in patients with CKD stage 3a and 75.2% in patients with CKD stage 3b at the WTP threshold

In CKD 3a, the results were robust, with the single exception of the utility for CKD

The results in CKD 3b were robust

Rebecca L. Tisdale 2022 [22]

scenario analyses, OWSA, and PSA

1 discontinuation of dapagliflozin after 2.4 years, the length of the DAPA-CKD trial, with the assumption that patients previously on dapagliflozin resume their hypothetical placebo eGFR progression trajectory at that time

2 CKD stage-dependent effectiveness of dapagliflozin such that effectiveness decreases in later stages

3 continual, constant effectiveness of dapagliflozin.

The results were robust.

the cost-effectiveness probability of dapagliflozin was 88.8%

the results were robust, with the single exception of the cost of dapagliflozin

Kriengsak Vareesangthip 2022 [23]

scenario analyses, OWSA, and PSA

Adding the treatment costs of minor adverse event slightly, dapagliflozin remains cost- effectiveness

the cost-effectiveness probability of dapagliflozin was 100.0%

the results were robust

zhong ling 2024 [24]

OWSA

N

N

the results were robust

Phil McEwan 2024 [28]

scenario analyses, OWSA, and PSA

Different time horizons: the results were robust.

In the UK, 99.8% of simulations were found to be cost effective, 99.9% were cost effective in Spain, whilst 100% were cost effective in Italy and in Japan

the results were robust

Buritica, M. P. 2022 (Conference Abstract) [16]

PSA

N

the results were consistent to the base case

N

Nava-Vargas 2023 (Conference Abstract) [1]

N

N

N

N

Phil McEwan 2021 (Conference Abstract) [19]

N

N

N

N

Ordoñez J 2022a (Conference Abstract) [25]

PSA

N

the probability that dapagliflozin is cost-effectiveness at 12 months is 93.6%, at 24 months, 93.5%, and at 32 months, 95.4%

N

Ordoñez J 2022b (Conference Abstract) [26]

PSA

N

the probability that dapagliflozin is cost-effectiveness at 12 months is 69.8%, at 24 months, 82.1%, and at 32 months, 88.4%

N

Ordoñez J 2022c (Conference Abstract) [27]

PSA

N

the probability that dapagliflozin is cost-effectiveness at 12 months is 96.3%, at 24 months, 94.5%, and at 32 months, 96.3%

N